antibody - International Pharmaceutical Industry

Volume 16 Issue 1

Advancing Therapeutic Solutions with Antibody-drug Conjugates (ADCs)

As promising therapeutic agents for treating oncology indications, antibody-drug conjugates (ADCs) have become prominent in the biopharmaceutical market in recent ye...

15 April 2024 Volume 16 Issue 1 | Editorial Archive ADCs | Advancing

Continue Reading →

Volume 15 Issue 3

Antibody Drug Conjugates and the Link to Fighting Cancer

Antibody drug conjugates (ADCs) are a big deal in oncology. And rightly so: they combine highly specific targeting with a potent cytotoxic payload to deliver tremend...

29 September 2023 Volume 15 Issue 3 ADCs | antibody

Continue Reading →

News

FDA approves single-vial version of GSK’s Menveo vaccine, ending need for reconstitution

GSK has won FDA approval for a single-vial formulation of its meningococcal disease vaccine Menveo, thereby ending the need for reconstitution that has existed since...

19 October 2022 News antibody | FDA approval

Continue Reading →

News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...

13 October 2021 News antibody | AstraZeneca

Continue Reading →

News

Roche withdraws US approval for Tecentriq in mTNBC

Roche has voluntarily withdrawn its US accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for the treatment of adults with unresectab...

1 September 2021 News antibody | atezolizumab

Continue Reading →

News

HK researchers invent universal antibody drug against HIV/AIDS

A team led by Professor Chen Zhiwei at Hong Kong University’s AIDS Institute says its discovery, tested on mice, shows the new antibody can help control the vir...

19 June 2018 News antibody | drug

Continue Reading →

News

Univercells granted €2.4M ($2.9M) to develop antibody production platform

Univercells SA, a technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions, today announces that it has received a grant&...

25 January 2018 News antibody | auto-immune

Continue Reading →

News

Avacta Group plc announces positive outcome of proof-of-concept study with Glythera and follow-on drug development partnership

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the develo...

16 January 2018 News antibody | biotherapeutics

Continue Reading →

News

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today...

16 January 2018 News antibody | drug discovery

Continue Reading →

News

SYGNIS AG signs supply agreement with US Biological for the Lightning-Link antibody labelling technology

SYGNIS AG, the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced it has signed a supply agreement with ...

28 November 2017 News antibody | biological

Continue Reading →